Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin‐Biroulet, Toshimitsu Fujii, Jessica R. Allegretti et al.|Gastroenterology|2023Cited by 97
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T. Rubin, Patrick Chamouard, Jessica R. Allegretti et al.|The Lancet|2024Cited by 95
Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammationFlavio Caprioli, Giovanni Monteleone, Carmine Stolfi et al.|Gut|2008Cited by 12
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)Gaetano Bergamaschi, Veronica Marasco, Fabiana Castiglione et al.|Digestive and Liver Disease|2024Cited by 6
OC.09.8 INTERLEUKIN-34 INDUCES CC-CHEMOKINE LIGAND 20 IN GUT EPITHELIAL CELLSEleonora Franzè, Giovanni Monteleone, Flavio Caprioli et al.|Digestive and Liver Disease|2016Cited by 0